Immunohistochemical expression of galectin-3 is significantly associated with grade, stage and differentiation of endometrial carcinomas

Al-Maghrabi, Jaudah; Abdelrahman, Amer Shafie; Ghabrah, Tawfik M.; Butt, Nadeem Shafique; Al-Maghrabi, Basim

doi:10.1016/j.prp.2017.01.012

Cited by 16 publications

(13 citation statements)

References 28 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…These levels decreased dramatically with increasing malignancy grade (p < 0:05) (Figure 1(b)). These findings are consistent 3 International Journal of Breast Cancer with results in other studies involving breast [8,18] and endometrial cancers [24].…”

Section: Extracellular Gal-3 Levels Decrease With Increasingsupporting

confidence: 89%

Elevated Soluble Galectin-3 as a Marker of Chemotherapy Efficacy in Breast Cancer Patients: A Prospective Study

Shafiq

Moore

Suleman

et al. 2020

International Journal of Breast Cancer

View full text Add to dashboard Cite

Purpose. Galectin-3 (Gal-3) is a glycan-binding lectin with a debated role in cancer progression due to its various functions and patterns of expression. The current study investigates the relationship between breast cancer prognosis and secreted Gal-3. Methods. Breast cancer patients with first time cancer diagnosis and no prior treatment (n=88) were placed in either adjuvant or neoadjuvant setting based on their treatment modality. Stromal and plasma Gal-3 levels were measured in each patient at the time of diagnosis and then throughout treatment using immunohistochemistry (IHC) and ELISA, respectively. Healthy women (>18 years of age, n=63) were used to establish baseline levels of plasma Gal-3. Patients were followed for 84 months for disease-free survival analysis. Results. Enhanced levels of plasma (adjuvant) and stromal (neoadjuvant) Gal-3 were found to be markers of chemotherapy efficacy. The patients with chemotherapy-induced increase in extracellular Gal-3 had longer disease-free interval and significantly lower rate of recurrence during 84-month follow-up compared to patients with unchanged or decreased secretion. Conclusion. The findings support the use of plasma Gal-3 as a marker for chemotherapy efficacy when no residual tumor is visible through imaging. Furthermore, stromal levels in any remaining tumors postchemotherapy can also be used to predict long-term prognosis in patients.

show abstract

Section: Extracellular Gal-3 Levels Decrease With Increasingsupporting

confidence: 89%

Elevated Soluble Galectin-3 as a Marker of Chemotherapy Efficacy in Breast Cancer Patients: A Prospective Study

Shafiq

Moore

Suleman

et al. 2020

International Journal of Breast Cancer

View full text Add to dashboard Cite

show abstract

“…1b). These findings are consistent with results in other studies involving breast [8,18] and endometrial cancers [24].…”

Section: Results: Extracellular Gal-3 Levels Decrease With Increasingsupporting

confidence: 93%

Elevated soluble Galectin-3 as a marker of chemotherapy efficacy in Breast cancer patients; a prospective study

Shafiq

Moore

Suleman

et al. 2020

Preprint

View full text Add to dashboard Cite

Soluble Gal-3 as a marker of chemotherapy efficacy in breast cancer 2 ABSTRACT:Purpose: Galectin-3 (Gal-3) is a glycan-binding lectin with a debated role in cancer progression due to its various functions and patterns of expression. The current study investigates the relationship between breast cancer prognosis and secreted Gal-3.Methods: Breast cancer patients with first time cancer diagnosis and no prior treatment (n=88) were placed in either adjuvant or neoadjuvant setting based on their treatment modality. Stromal and plasma Gal-3 levels were measured in each patient at the time of diagnosis and then throughout treatment using immunohistochemistry (IHC) and ELISA respectively. Healthy women (>18 years of age, n=63) were used to establish baseline levels of plasma Gal-3. Patients were followed for 84 months for disease free survival analysis.Results: Enhanced levels of plasma (adjuvant) and stromal (neo-adjuvant) Gal-3 were found to be markers of chemotherapy efficacy. The patients with chemotherapy induced increase in extracellular Gal-3 had longer disease-free interval and significantly lower rate of recurrence during 84-month follow-up compared to patients with unchanged or decreased secretion. Conclusion:The findings support the use of plasma Gal-3 as a marker for chemotherapy efficacy when no residual tumor is visible through imaging. Furthermore, stromal levels in any remaining tumors post chemotherapy can also be used to predict long term prognosis in patients.

show abstract

“…Completely different results suggestive of the great proapoptotic effect of galectin 3 can be found in the study by AL Maghrabi [ 24 ]. As reported by the author, galectin 3 levels were strictly associated with tumor suppression.…”

Section: Discussionmentioning

confidence: 90%

Could Galectin 3 Be a Good Prognostic Factor in Endometrial Cancer?

et al. 2020

View full text Add to dashboard Cite

Galectin 3 is a modulator of several basic biological functions. It may be involved in the development of obesity and type 2 diabetes—risk factors of endometrial cancer. The study involved 144 patients, after abrasion due to postmenopausal bleeding. Galectin 3 concentrations were quantified in serum by multiplex fluorescent bead-based immunoassays. Median serum galectin 3 concentrations revealed significant differences between FIGO III and IV vs. FIGO I and II patients. Statistically higher concentrations were reported for patients with lymph node metastases compared to patients without it (p = 0.001) as well as in patients with lymphovascular space invasion compared to patients without LVSI (p = 0.02). No statistically significant differences were observed for median of galectin 3 levels depending on the surgical procedure (laparoscopy vs. laparotomy, p = 0.0608). Patients with galectin 3 levels exceeding the median value were characterized by overall survival being shorter by 11.9 months. High levels of galectin 3 were correlated with shorter disease-free survival, the difference is up to 14.8 months. Galectin 3 can be an independent prognostic factor in patients with endometrial cancer. Among the recognized prognostic factors and the concentrations of the galectin 3 marker at the adopted time points, the univariate analysis showed a significant effect of staging, grading, and cutoff galectin 3 on the OS. For multivariate analysis, the galectin 3 cutoff point had the greatest significant impact on OS.

show abstract

Immunohistochemical expression of galectin-3 is significantly associated with grade, stage and differentiation of endometrial carcinomas

Cited by 16 publications

References 28 publications

Elevated Soluble Galectin-3 as a Marker of Chemotherapy Efficacy in Breast Cancer Patients: A Prospective Study

Elevated Soluble Galectin-3 as a Marker of Chemotherapy Efficacy in Breast Cancer Patients: A Prospective Study

Elevated soluble Galectin-3 as a marker of chemotherapy efficacy in Breast cancer patients; a prospective study

Could Galectin 3 Be a Good Prognostic Factor in Endometrial Cancer?

Contact Info

Product

Resources

About